Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer
September 6, 2024 5:07 AM EDTOppenheimer analyst Justin Kim raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $42.00 (from $38.00) while maintaining a Outperform rating.
The analyst comments "On Thursday PHVS presented 2 oral presentations and 10 posters at the bradykinin symposium focused on HAE. Critical to the PHVS... More
